Company Filing History:
Years Active: 2019
Title: Delphine Desigaud: Innovator in Antibody Drug Conjugates
Introduction
Delphine Desigaud is a prominent inventor based in Toulouse, France. She has made significant contributions to the field of biotechnology, particularly in the development of antibody drug conjugates. Her innovative work focuses on creating novel antibodies that can be used in targeted cancer therapies.
Latest Patents
Delphine Desigaud holds 1 patent for her invention titled "Antibodies, antibody drug conjugates and methods of use." This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC), and novel antibodies. The ADC, AC, and antibodies disclosed specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II). These innovations can be utilized to treat and identify AMHR-II expressing cancers, including prostate cancer, breast cancer, and various gynecologic cancers, particularly metastatic ovarian cancer.
Career Highlights
Desigaud is currently associated with Gamamabs Pharma SA, where she continues to advance her research in antibody drug conjugates. Her work is pivotal in the ongoing fight against cancers that express AMHR-II, contributing to the development of targeted therapies that can improve patient outcomes.
Collaborations
Some of her notable coworkers include Olivier Dubreuil and Jean-Marc Barret, who collaborate with her in the pursuit of innovative cancer treatments.
Conclusion
Delphine Desigaud's contributions to the field of biotechnology, particularly through her patent on antibody drug conjugates, highlight her role as a key innovator in cancer treatment. Her work continues to pave the way for advancements in targeted therapies that can significantly impact patient care.